Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Congress Park Capital LLC

Congress Park Capital LLC lessened its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 17.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,035,617 shares of the biotechnology company's stock after selling 419,878 shares during the quarter. Heron Therapeutics accounts for about 1.7% of Congress Park Capital LLC's holdings, making the stock its 18th biggest holding. Congress Park Capital LLC owned approximately 1.34% of Heron Therapeutics worth $4,478,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of HRTX. Point72 Asset Management L.P. purchased a new position in shares of Heron Therapeutics in the fourth quarter valued at approximately $4,706,000. Stonepine Capital Management LLC purchased a new position in shares of Heron Therapeutics in the fourth quarter valued at approximately $1,071,000. Quinn Opportunity Partners LLC purchased a new position in shares of Heron Therapeutics in the fourth quarter valued at approximately $581,000. JPMorgan Chase & Co. boosted its stake in shares of Heron Therapeutics by 172.2% in the fourth quarter. JPMorgan Chase & Co. now owns 562,764 shares of the biotechnology company's stock valued at $861,000 after purchasing an additional 356,053 shares during the period. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Heron Therapeutics in the fourth quarter valued at approximately $459,000. Hedge funds and other institutional investors own 80.01% of the company's stock.

Heron Therapeutics Stock Up 5.5%

Heron Therapeutics stock traded up $0.11 during trading on Monday, reaching $2.11. The stock had a trading volume of 2,117,935 shares, compared to its average volume of 2,215,415. Heron Therapeutics, Inc. has a 52-week low of $1.04 and a 52-week high of $3.73. The business has a 50 day moving average price of $2.04 and a 200 day moving average price of $1.93. The stock has a market cap of $321.90 million, a PE ratio of -35.17 and a beta of 1.16.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.01) by $0.02. The firm had revenue of $38.90 million during the quarter, compared to analysts' expectations of $37.08 million. On average, equities analysts predict that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on HRTX. Needham & Company LLC reissued a "buy" rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research note on Friday, April 11th. Wall Street Zen raised shares of Heron Therapeutics from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. Finally, HC Wainwright began coverage on shares of Heron Therapeutics in a research note on Monday, June 9th. They issued a "buy" rating and a $6.00 price objective for the company.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.